Safety and Efficacy of Sustained Erythropoietin Therapy of Anemia in Chronic Kidney Disease Patients and End-Stage Renal Disease (ESRD) Dialysis Patients Using MDGN201 TARGTEPO

Trial Profile

Safety and Efficacy of Sustained Erythropoietin Therapy of Anemia in Chronic Kidney Disease Patients and End-Stage Renal Disease (ESRD) Dialysis Patients Using MDGN201 TARGTEPO

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs MDGN 201 (Primary)
  • Indications Anaemia
  • Focus Pharmacokinetics
  • Sponsors Aevi Genomic Medicine
  • Most Recent Events

    • 17 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 09 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Mar 2017.
    • 09 Jan 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top